As we prepare to say 'so long, farewell' to 2016, we'd like to take the opportunity to thank all our blog readers and subscribers. Read on for a round up of our most read topics from the year....
In no particular order, the most popular 6 blog posts from across our subject matter areas in 2016 were:
In July 2016, Cytel announced the publication of an important article in the New England Journal of Medicine. The The review article, Adaptive Designs for Clinical Trials was co-authored by Cytel’s President and Co-Founder Cyrus Mehta and Deepak L. Bhatt, M.D., M.P.H of Brigham and Women’s Hospital Heart and Vascular Center and Harvard Medical School (D.L.B.) and Harvard School of Public Health (C.M.). The article promotes a better understanding of adaptive designs particularly in a confirmatory setting - and in this blog we shared some of its highlights.
R is one of the most commonly used data-analytics and machine-learning languages in the world right now. Within the pharmaceutical industry though, it’s traditionally been a somewhat different story, with trends not necessarily replicating the broader business environment. However, it’s clear that while uptake of R in pharma may be slower than general industry, the skills landscape does appear to be changing.
This is a topic very close to our hearts at Cytel. We believe that strong alignment between data management and biostatistics groups is critical to ensure quality delivery. In this blog, we highlight some of the interactions between data management and statistics groups that really make a difference.
In this blog, our data management experts share the 6 critical steps which can ensure the clinical database is locked on time, or even ahead of schedule. And as a bonus- check out our popular infographic which clearly outlines the steps.
One of the barriers to uptake of adaptive designs is lack of case studies. Earlier in 2016, NIHR and University of Sheffield researchers published a paper, ‘Adaptive designs undertaken in clinical research: a review of registered clinical trials’(Hatfield et al) exploring the current state of adaptive designs in practice. In this blog we caught up with Munya Dimairo, NIHR Research fellow and one of the paper’s co-authors to find out more.
Traceablility of clinical data is necessary to ensure transparency and understanding. In this blog, CDISC expert Angelo Tinazzi guides us through the situations where traceability can break down, and helps us to separate our data point traceability from our metadata traceability.
Do you enjoy our blogs? Sign up for updates directly to your inbox and ensure you get 2017 off to a great start!